You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Claims for Patent: 12,508,313

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,508,313

Title:	Quinoline derivative-containing pharmaceutical composition
Abstract:	A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof; and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: wherein, R1 is a hydrogen atom, a C1-6 alkyl group or a C3-8 cycloalkyl group; and R2 is a hydrogen atom or a methoxy group.
Inventor(s):	Masashi Bando
Assignee:	Eisai R&D Management Co Ltd
Application Number:	US17/228,025
Patent Claims:	1. A pharmaceutical composition, comprising: (1) 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; (2) an alkaline earth metal carbonate wherein the weight ratio of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate to the alkaline earth metal carbonate is from 1:0.25 to 1:26.4; and (3) a disintegrating agent, wherein the alkaline earth metal carbonate is magnesium carbonate or calcium carbonate. 2. The composition of claim 1, wherein the alkaline earth metal carbonate is magnesium carbonate. 3. The composition of claim 1, wherein the alkaline earth metal carbonate is calcium carbonate. 4. The composition of claim 2, wherein the disintegrating agent is carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose, or crospovidone. 5. The composition of claim 4, wherein the disintegrating agent is low-substituted hydroxypropylcellulose. 6. The composition of claim 2, wherein the weight ratio of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate to the magnesium carbonate is from 1:1 to 1:25. 7. The composition of claim 2, wherein 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate is present in an amount from 1 wt % to 12.5 wt %. 8. The composition of claim 2, wherein the composition is in a capsule dosage form. 9. The composition of claim 2, wherein the composition is in a tablet dosage form. 10. The composition of claim 2, wherein the composition is in a granular form. 11. The composition of claim 3, wherein the disintegrating agent is carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose, or crospovidone. 12. The composition of claim 11, wherein the disintegrating agent is low-substituted hydroxypropylcellulose. 13. The composition of claim 12, wherein the composition further comprises mannitol, hydroxypropylcellulose, microcrystalline cellulose, and talc. 14. The composition of claim 3, wherein the weight ratio of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate to the calcium carbonate is from 1:1 to 1:25. 15. The composition of claim 3, wherein 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate is present in an amount from 1 wt % to 12.5 wt %. 16. The composition of claim 15, wherein the calcium carbonate is present in an amount ranging from 10 to 40 wt %. 17. The composition of claim 3, wherein the composition is in a capsule dosage form. 18. The composition of claim 11, wherein the composition is in a capsule dosage form. 19. The composition of claim 12, wherein the composition is in a capsule dosage form. 20. The composition of claim 13, wherein the composition is in a capsule dosage form. 21. The composition of claim 14, wherein the composition is in a capsule dosage form. 22. The composition of claim 15, wherein the composition is in a capsule dosage form. 23. The composition of claim 16, wherein the composition is in a capsule dosage form. 24. The composition of claim 3, wherein the composition is in a tablet dosage form. 25. The composition of claim 11, wherein the composition is in a tablet dosage form. 26. The composition of claim 12, wherein the composition is in a tablet dosage form. 27. The composition of claim 3, wherein the composition is in a granular form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.